JP2016190871A5 - - Google Patents

Download PDF

Info

Publication number
JP2016190871A5
JP2016190871A5 JP2016153607A JP2016153607A JP2016190871A5 JP 2016190871 A5 JP2016190871 A5 JP 2016190871A5 JP 2016153607 A JP2016153607 A JP 2016153607A JP 2016153607 A JP2016153607 A JP 2016153607A JP 2016190871 A5 JP2016190871 A5 JP 2016190871A5
Authority
JP
Japan
Prior art keywords
nhc
independently
conjugate according
valence bond
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016153607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016190871A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016190871A publication Critical patent/JP2016190871A/ja
Publication of JP2016190871A5 publication Critical patent/JP2016190871A5/ja
Withdrawn legal-status Critical Current

Links

JP2016153607A 2009-08-06 2016-08-04 長期のインビボ有効性を有する成長ホルモン Withdrawn JP2016190871A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09167350.9 2009-08-06
EP09167350 2009-08-06
US23296709P 2009-08-11 2009-08-11
US61/232,967 2009-08-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523348A Division JP6086528B2 (ja) 2009-08-06 2010-08-06 長期のインビボ有効性を有する成長ホルモン

Publications (2)

Publication Number Publication Date
JP2016190871A JP2016190871A (ja) 2016-11-10
JP2016190871A5 true JP2016190871A5 (cg-RX-API-DMAC7.html) 2016-12-22

Family

ID=41343110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523348A Active JP6086528B2 (ja) 2009-08-06 2010-08-06 長期のインビボ有効性を有する成長ホルモン
JP2016153607A Withdrawn JP2016190871A (ja) 2009-08-06 2016-08-04 長期のインビボ有効性を有する成長ホルモン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523348A Active JP6086528B2 (ja) 2009-08-06 2010-08-06 長期のインビボ有効性を有する成長ホルモン

Country Status (5)

Country Link
US (4) US8841249B2 (cg-RX-API-DMAC7.html)
EP (1) EP2461831B1 (cg-RX-API-DMAC7.html)
JP (2) JP6086528B2 (cg-RX-API-DMAC7.html)
CN (2) CN105963710A (cg-RX-API-DMAC7.html)
WO (1) WO2011015649A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR0008759B1 (pt) 1999-01-14 2014-03-11 Bolder Biotechnology Inc Métodos para a produção de proteinas contendo resíduos de cisteina livre
CN105963710A (zh) * 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
US20140018290A1 (en) 2011-01-26 2014-01-16 Novo Nordisk A/S Leptin derivatives
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
BR112016004355A2 (pt) * 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
EP3348635B1 (en) 2015-09-08 2021-02-17 JCR Pharmaceuticals CO., LTD. Novel human serum albumin mutant
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
JP2017165713A (ja) 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP4047006A4 (en) 2019-10-17 2023-11-01 JCR Pharmaceuticals Co., Ltd. Method for producing fusion protein of serum albumin and growth hormone
CN114728043B (zh) 2019-10-30 2024-04-16 Jcr制药股份有限公司 含有血清白蛋白与生长激素的融合蛋白的水性药物组合物
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11752539B2 (en) * 2020-01-27 2023-09-12 Panduit Corp. Embossing system
KR20250075985A (ko) * 2023-11-22 2025-05-29 한도숙 상처 치료 또는 피부 주름형성 억제용 조성물

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE68929273T2 (de) 1988-08-24 2001-07-05 American Cyanamid Co., Wayne Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
EP0555649B1 (en) 1992-01-14 2004-12-08 Ajinomoto Co., Inc. Gene encoding transglutaminase derived from fish
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JP3758187B2 (ja) 1994-01-28 2006-03-22 味の素株式会社 マガキ由来のトランスグルタミナーゼ
ES2267103T3 (es) 1994-08-26 2007-03-01 Novozymes A/S Transglutaminasas microbianas, su produccion y uso.
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
NZ298746A (en) 1995-01-19 1998-07-28 Novo Nordisk As Transglutaminases from oomcyetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
JP3628333B2 (ja) 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO1998013381A1 (fr) 1996-09-26 1998-04-02 Ajinomoto Co., Inc. Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
PL202367B1 (pl) 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
ATE406384T1 (de) 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
OA13063A (en) 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003087139A2 (en) 2002-04-10 2003-10-23 Eli Lilly And Company Treatment of gastroparesis
BR0309576A (pt) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ATE455555T1 (de) 2003-02-19 2010-02-15 Ipsen Pharma Glp-1-analoga
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
EP1503283A1 (en) * 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007508250A (ja) 2003-10-10 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 持続性放出製剤における長期作用性分子
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
CA2559889A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
AU2005261740A1 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EP1778838A2 (en) 2004-08-02 2007-05-02 Novo Nordisk Health Care AG Conjugation of fvii
KR20070042567A (ko) 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TW200716179A (en) * 2005-06-15 2007-05-01 Novo Nordisk As Transglutaminase mediated conjugation of growth hormone
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
CN101263225A (zh) 2005-08-18 2008-09-10 诺沃-诺迪斯克保健股份有限公司 改进转谷氨酰胺酶的底物特异性
US20090082254A1 (en) 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
KR100739988B1 (ko) * 2006-06-28 2007-07-16 주식회사 하이닉스반도체 플래쉬 메모리 소자의 제조방법
JP5252458B2 (ja) * 2006-07-07 2013-07-31 ノボ ノルディスク ヘルス ケア アーゲー 新規タンパク質コンジュゲート及びその製造方法
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
JP2010500886A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
BRPI0716261A2 (pt) 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
JP5390404B2 (ja) 2007-02-16 2014-01-15 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための環状部分を有する化合物及び組成物
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
KR20110039348A (ko) * 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
CN105963710A (zh) * 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
RU2605627C2 (ru) * 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo

Similar Documents

Publication Publication Date Title
JP2016190871A5 (cg-RX-API-DMAC7.html)
JP2011529948A5 (cg-RX-API-DMAC7.html)
WO2012112350A3 (en) Dental compositions comprising ethylenically unsaturated addition-fragmentation agent
CL2019001069A1 (es) Métodos para el tratamiento de atrofia muscular y enfermedad ósea con el uso de proteínas trap híbridas novedosas del ligando actriib.
RU2012134975A (ru) Гормоны роста с пролонгированной эффективностью in vivo
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
JP2015518821A5 (cg-RX-API-DMAC7.html)
JP2017521436A5 (cg-RX-API-DMAC7.html)
JP2016529195A5 (cg-RX-API-DMAC7.html)
JP2017141277A5 (cg-RX-API-DMAC7.html)
JP2019048806A5 (cg-RX-API-DMAC7.html)
JP2012513416A5 (cg-RX-API-DMAC7.html)
EP0110429A2 (de) Verzögerer für die Polymerisation von Aziridinverbindungen
JP2010505865A5 (cg-RX-API-DMAC7.html)
JP2021501760A5 (cg-RX-API-DMAC7.html)
RU2013145949A (ru) Способ получения катализатора на основе цеолита для превращения метанола в олефины
JP2019512490A5 (cg-RX-API-DMAC7.html)
MX2021001221A (es) Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
JP2015509966A5 (cg-RX-API-DMAC7.html)
JP2021504302A5 (cg-RX-API-DMAC7.html)
JP2017503016A5 (cg-RX-API-DMAC7.html)
JP2020504184A5 (cg-RX-API-DMAC7.html)
EP4435013A3 (en) Process for preparing multi- or dual-headed compositions useful for chain shuttling
WO2020102053A8 (en) Methods of preparing cytotoxic benzodiazepine derivatives
JP2021158120A5 (cg-RX-API-DMAC7.html)